Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

  title={Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.},
  author={Javier Cort{\'e}s and Virgina Calvo and Natalia Ram{\'i}rez-Merino and Joyce O'Shaughnessy and Adam M. Brufsky and Nicholas Robert and Merc{\`e} Vidal and Eva Erice Mu{\~n}oz and Javier Blanco P{\'e}rez and Shabbir Dawood and Cristina Band{\'i}n Saura and Serena Di Cosimo and Antonio J Gonz{\'a}lez-Mart{\'i}n and Meritxell Bellet and O. da Costa e Silva and David Miles and Antonio C Llombart and Jos{\'e} Baselga},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  volume={23 5},
BACKGROUND Bevacizumab is a monoclonal antibody against vascular endothelial growth factor with the ability to increase progression-free survival in metastatic breast cancer (MBC). A systematic review and meta-analysis was conducted to determine the risk of the most clinically relevant adverse outcomes associated with the use of bevacizumab in the treatment of breast cancer. PATIENTS AND METHODS We included phase III clinical trials that used bevacizumab alone or in combination with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 11 times over the past 90 days. VIEW TWEETS
23 Extracted Citations
25 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 23 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 25 references

Avastin (Bevacizumab) FDA Drug Label 2008: http://

  • Genentech, Inc
  • Date last accessed)
  • 2011

Similar Papers

Loading similar papers…